Literature DB >> 19520920

Cellular markers of muscle atrophy in chronic obstructive pulmonary disease.

Pamela J Plant1, Dina Brooks, Marie Faughnan, Tanya Bayley, James Bain, Lianne Singer, Judy Correa, Dawn Pearce, Matthew Binnie, Jane Batt.   

Abstract

Skeletal muscle atrophy in individuals with advanced chronic obstructive pulmonary disease (COPD) is associated with diminished quality of life, increased health resource use, and worsened survival. Muscle wasting results from an imbalance between protein degradation and synthesis, and is enhanced by decreased regenerative repair. We investigated the activation of cellular signaling networks known to mediate muscle atrophy and regulate muscle regenerative capacity in rodent models, in individuals with COPD (FEV(1) < 50% predicted). Nine patients with COPD and nine control individuals were studied. Quadriceps femoris muscle isometric contractile force and cross-sectional area were confirmed to be significantly smaller in the patients with COPD compared with control subjects. The vastus lateralis muscle was biopsied and muscle transcript and/or protein levels of key components of ubiquitin-mediated proteolytic systems (MuRF1, atrogin-1, Nedd4), inflammatory mediators (IkappaBalpha, NF-kappaBp65/p50), AKT network (AKT, GSK3beta, p70S6 kinase), mediators of autophagy (beclin-1, LC3), and myogenesis (myogenin, MyoD, Myf5, myostatin) were determined. Atrogin-1 and Nedd4, two ligases regulating ubiquitin-mediated protein degradation and myostatin, a negative regulator of muscle growth, were significantly increased in the muscle of patients with COPD. MuRF1, Myf5, myogenin, and MyoD were not differentially expressed. There were no differences in the level of phosphorylation of AKT, GSK3beta, p70S6kinase, or IkappaBalpha, activation of NF-kappaBp65 or NF-kappaBp50, or level of expression of beclin-1 or LC3, suggesting that AKT signaling was not down-regulated and the NF-kappaB inflammatory pathway and autophagy were not activated in the COPD muscle. We conclude that muscle atrophy associated with COPD results from the recruitment of specific regulators of ubiquitin-mediated proteolytic pathways and inhibition of muscle growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520920     DOI: 10.1165/rcmb.2008-0382OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  72 in total

1.  Molecular adaptations to aerobic exercise training in skeletal muscle of older women.

Authors:  Adam R Konopka; Matthew D Douglass; Leonard A Kaminsky; Bozena Jemiolo; Todd A Trappe; Scott Trappe; Matthew P Harber
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-06-21       Impact factor: 6.053

2.  NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy.

Authors:  Ramon C J Langen; Astrid Haegens; Juanita H J Vernooy; Emiel F M Wouters; Menno P J de Winther; Harald Carlsen; Chad Steele; Steven E Shoelson; Annemie M W J Schols
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-26       Impact factor: 6.914

3.  The role of Interleukin 15 in protein degradation in skeletal muscles in rats of chronic obstructive pulmonary disease.

Authors:  Zhaohui Liu; Wei Fan; Jinlong Chen; Zhike Liang; Lijun Guan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

Review 5.  Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease?

Authors:  Ramzi Lakhdar; Roberto A Rabinovich
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 6.  Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.

Authors:  Sue C Bodine; Leslie M Baehr
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-05       Impact factor: 4.310

7.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

8.  NF-κB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy.

Authors:  Chia-Ling Wu; Evangeline W Cornwell; Robert W Jackman; Susan C Kandarian
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-19       Impact factor: 4.249

Review 9.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

10.  Superoxide release from contracting skeletal muscle in pulmonary TNF-α overexpression mice.

Authors:  Li Zuo; Allison H Hallman; William J Roberts; Peter D Wagner; Michael C Hogan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-11-06       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.